Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ.Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 376 manuscripts (scopus citations:124,208; h-index:141; IF:8,590). Top 1% most cited researcher globally by Clarivate Analytics (2014-24), and world most cited investigator in liver cancer. Major achievements: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets in liver cancer, and c) Establishing standard therapies for HCC: sorafenib, regorafenib, ramucirumab, TACE and TACE plus lenvatinib+pembrolizumab. He is Editor-in-Chief of J HEP Reports (IF:9.5), Founder and President of ILCA, delivered > 700 lectures, and PI of ~110 competitive grants [coordinator of 2 European FP7 & Horizon Europe grants and 2 NIH-RO1].

Prof Josep M. Llovet research has been focused on clinical and translational studies in liver cancer for the last 30 years. He is leading international randomized trials on immunotherapies and European and international consortiums for liver cancer research assessing molecular mechanism of response to immunotherapies. His main areas of interest are a) characterize the human atlas of immune populations in liver cancer b) identify mechanisms and biomarkers predicting response and resistance to checkpoint inhibitors for hepatocellular carcinoma (HCC) through single-cell data and spatial transcriptomics, NGS and artificial intelligence; c) translate oncogenic drivers discoveries as targeted therapies in liver cancer, d) exploring the role of liver microbiome in the pathogenesis of HCC. e) identification of drugs which, when combined, have synergistic effects; f) improving knowledge about the mechanisms involved in the origin, progression and dissemination of MASH-HCC.